内科学(呼吸器)

Medicine & Life Sciences

1. Lung 100%
2. Non-Small Cell Lung Carcinoma 86%
3. Coronavirus 82%
4. Mycobacterium avium Complex 81%
5. Chronic Obstructive Pulmonary Disease 75%
6. Asthma 66%
7. Lung Neoplasms 65%
8. Lung Diseases 64%
9. Japan 54%
10. Emphysema 37%
11. Pneumonia 36%
12. Adenocarcinoma of Lung 36%
13. osimertinib 35%
14. Tomography 34%
15. Mutation 34%
16. Protein-Tyrosine Kinases 32%
17. ErbB Receptors 31%
18. Therapeutics 31%
19. Bronchoalveolar Lavage Fluid 30%
20. Inflammation 28%
21. Eosinophils 26%
22. SARS Virus 26%
23. Interstitial Lung Diseases 23%
24. Serum 23%
25. Lymphocytes 23%
26. Advisory Committees 22%
27. Respiratory Function Tests 21%
28. Severe Acute Respiratory Syndrome 21%
29. Pulmonary Emphysema 20%
30. Neoplasms 20%
31. Cytokines 20%
32. Standing Position 20%
33. Tobacco Products 20%
34. Adrenal Cortex Hormones 20%
35. Smoke 20%
36. Infections 18%
37. Supine Position 17%
38. Elderly 17%
39. Pancreatic Elastase 17%
40. Genes 15%
41. Alveolar Epithelial Cells 15%
42. Quality of Life 15%
43. Forced Expiratory Volume 15%
44. Insertional Mutagenesis 15%
45. Neutrophils 14%
46. Retrospective Studies 14%
47. Obstructive Sleep Apnea 14%
48. Exons 13%
49. Phenotype 13%
50. Macrophages 13%
51. Antibodies 13%
52. Drug Therapy 13%
53. Cohort Studies 13%
54. dupilumab 13%
55. Pneumococcal Infections 13%
56. Biomarkers 13%
57. Neutralizing Antibodies 13%
58. Epithelial Cells 13%
59. Cross-Sectional Studies 12%
60. Safety 12%
61. Small Cell Lung Carcinoma 12%
62. thymic stromal lymphopoietin 12%
63. University Hospitals 12%
64. Smoking 12%
65. Population 12%
66. Bacterial Pneumonia 12%
67. Stem Cells 12%
68. Fibroblast Growth Factor 9 12%
69. Afatinib 11%
70. Sputum 11%
71. T-Lymphocytes 11%
72. Allergic Bronchopulmonary Aspergillosis 11%
73. Clarithromycin 11%
74. Platelet Activating Factor 11%
75. Acute Lung Injury 10%
76. Organoids 10%
77. Odds Ratio 10%
78. Bronchiectasis 10%
79. Nivolumab 10%
80. Amikacin 10%
81. Mycobacterium avium 10%
82. Physicians 10%
83. Steroids 10%
84. Interleukin-33 10%
85. Meta-Analysis 10%
86. Pharmacokinetics 9%
87. Multicenter Studies 9%
88. Confidence Intervals 9%
89. Interleukin-6 9%
90. Osteoporosis 9%
91. cysteinyl-leukotriene 9%
92. Human Influenza 9%
93. Body Mass Index 9%
94. Cell Line 9%
95. Thorax 9%
96. Systematic Reviews 9%
97. prostaglandin D2 receptor 9%
98. Smartphone 9%
99. 5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid 9%
100. Erlotinib Hydrochloride 9%